Edition:
United States

Ablynx NV (ABLX.OQ)

ABLX.OQ on NASDAQ Stock Exchange Global Select Market

54.16USD
12:33pm EST
Change (% chg)

$-0.19 (-0.35%)
Prev Close
$54.35
Open
$54.13
Day's High
$54.20
Day's Low
$54.05
Volume
14,157
Avg. Vol
--
52-wk High
$54.87
52-wk Low
$17.75

Latest Key Developments (Source: Significant Developments)

Sanofi CFO Refuses To Provide 2018 Outlook Excluding Recent Acquisitions Of Bioverativ, Ablynx
Wednesday, 7 Feb 2018 04:28am EST 

Feb 7 (Reuters) - Sanofi ::CFO REFUSES TO PROVIDE 2018 OUTLOOK EXCLUDING RECENT ACQUISITIONS OF BIOVERATIV, ABLYNX.CEO SAYS GROUP REMAINS “VERY COMMITTED” TO DENGVAXIA PROGRAM.CEO SAYS HAS REDUCED DIABETES AND CARDIOVASCULAR SALES STAFF BY 400 LAST YEAR IN THE U.S.CEO SAYS GROUP PLANS NO RESTRUCTURING MEASURES IN THE U.S THIS YEAR.  Full Article

Sanofi CFO sees cost of debt to finance Ablynx acquisition around 1 pct
Monday, 29 Jan 2018 08:38am EST 

Jan 29 (Reuters) - Sanofi Chief Financial Officer Jerome Contamine says::expects cost of debt to finance Ablynx acquisition to be around 1 percent.  Full Article

Ablynx Chairman, Peter Fellner, Resigns With Immediate Effect​
Monday, 8 Jan 2018 11:31am EST 

Jan 8 (Reuters) - ABLYNX NV ::ABLYNX ANNOUNCES BOARD CHANGES‍.DR PETER FELLNER DECIDED TO RESIGN FROM BOARD WITH IMMEDIATE EFFECT​.‍HE WILL BE SUCCEEDED BY DR BO JESPER HANSEN​.  Full Article

Ablynx's Board Says Takeover Proposal From Novo Nordisk Undervalues Company
Monday, 8 Jan 2018 07:25am EST 

Jan 8 (Reuters) - ABLYNX NV ::BOARD UNANIMOUSLY CONCLUDED THAT PROPOSAL FUNDAMENTALLY UNDERVALUES ABLYNX AND ITS STRONG PROSPECTS FOR CONTINUED GROWTH AND VALUE CREATION.TODAY CONFIRMED THAT ON DEC 22, 2017 IT RECEIVED UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK A/S.J.P. MORGAN IS SERVING AS FINANCIAL ADVISOR TO ABLYNX.ABLYNX STRONGLY BELIEVES UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK FUNDAMENTALLY UNDERVALUES THE COMPANY AND ITS FUTURE PROSPECTS.CO LONG-TERM STRATEGIC PLAN OF BECOMING FULLY INTEGRATED BIOPHARMACEUTICAL COMPANY."BOARD SEES NO MERIT IN CEDING CONTROL OF ITS ASSETS WITHOUT FULL UPFRONT VALUE RECOGNITION FOR SHAREHOLDERS" - CEO.  Full Article

Novo Nordisk CFO Says Not Our Understanding That Any Other Bidder Is Pursuing Ablynx
Monday, 8 Jan 2018 03:14am EST 

Jan 8 (Reuters) - NOVO NORDISK NOVOB.CO CHIEF FINANCIAL OFFICER JESPER BRANDGAARD SAID ON A CONFERENCE CALL IN RELATION TO BID FOR ABLYNX ::"IN TERMS OF COUNTER PROPOSALS IT IS NOT OUR UNDERSTANDING THAT ANY OTHER BIDDER IS PURSUING THE TARGET" nFWN1P3016.  Full Article

Novo Nordisk has proposed to buy Ablynx for up to 30.50 euros per share in cash
Monday, 8 Jan 2018 12:42am EST 

Jan 8 (Reuters) - Novo Nordisk ::HAS PROPOSED TO BUY ABLYNX FOR UP TO EUR 30.50 PER SHARE IN CASH, CONSISTING OF EUR 28.00 UPFRONT AND EUR 2.50 IN CONTINGENT VALUE RIGHTS​.‍PROPOSAL IMPLIES A TOTAL EQUITY VALUATION OF APPROXIMATELY EUR 2.6 BILLION FOR ABLYNX​.PROPOSAL IS SECOND PROPOSAL THAT CO HAS MADE TO ABLYNX'S BOARD AND REPRESENTS UP TO APPROXIMATELY A 14% INCREASE OVER FIRST PROPOSAL​.CO "REGRETS" THAT BOARD OF ABLYNX HAS SO FAR DECLINED TO ENGAGE IN ANY DISCUSSIONS, DESPITE PROPOSALS WHICH HAVE BEEN PUT FORWARD​.PROPOSAL ALSO CONSISTS OF ONE CONTINGENT VALUE RIGHT WITH TOTAL POTENTIAL CASH PAYMENTS OVER TIME OF UP TO EUR 2.50 PER SHARE​.  Full Article

Ablynx 9-month revenues decrease to 44.7 million euros ​
Thursday, 16 Nov 2017 01:21am EST 

Nov 16 (Reuters) - ABLYNX NV : :9 MONTH REVENUES OF EUR 44.7 MILLION (2016: EUR 68.9 MILLION)​.9 MONTH ‍OPERATING LOSS OF EUR 42.1 MILLION (2016: EUR 13.6 MILLION)​.‍9 MONTH NET CASH BURN OF EUR 26.9 MILLION (2016: EUR 44.1 MILLION)​.9 MONTH ‍CASH POSITION OF EUR 208.6 MILLION (2016: EUR 263.6 MILLION)​.‍9 MONTH ENDED WITH NET LOSS OF EUR 45.8 MILLION (2016: NET PROFIT OF EUR 10.9 MILLION)​.  Full Article

Ablynx announces full exercise of underwriters' option to purchase additional shares
Friday, 27 Oct 2017 01:21am EDT 

Oct 27 (Reuters) - ABLYNX NV ::ABLYNX ANNOUNCES FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES AND END OF STABILIZATION PERIOD.‍GREENSHOE OPTION GRANTED TO UNDERWRITERS FOR PURCHASE OF UP TO AN ADDITIONAL 1,714,500 NEW ORDINARY SHARES​.‍GREENSHOE EXERCISE BRINGS TOTAL GROSS PROCEEDS FOR OFFERING TO APPROXIMATELY $230 MILLION (EUR 195 MILLION)​.  Full Article

Ablynx ADS open at $17.85 in debut, 2 pct above IPO price ‍​
Wednesday, 25 Oct 2017 10:11am EDT 

Oct 25 (Reuters) - :Ablynx ADS open at $17.85 in debut on the NASDAQ versus IPO price of $17.50 per ADS‍‍​.  Full Article

Ablynx prices $200 mln IPO in the United States
Tuesday, 24 Oct 2017 08:08pm EDT 

Oct 24 (Reuters) - Ablynx NV : :Ablynx prices $200 million initial public offering in the United States.Ablynx NV - ‍prices us IPO totaling $200 million proceeds from sale of 11.43 million shares in form of American depositary shares at price of $17.50/ADS​.  Full Article

BRIEF-Ablynx Announces Option Exercise By Sanofi To License Two Additional Target Combinations​

* ABLYNX ANNOUNCES OPTION EXERCISE BY SANOFI FOR TWO ADDITIONAL MULTI-SPECIFIC NANOBODY PRODUCT CANDIDATES